Evidence map›Paper›PMID 23087782›Full record

ArticleJournal of antivirals & antiretrovirals2011

Validation of A Point-of-Care Lactate Device For Screening At-Risk Adults Receiving Combination Antiretroviral Therapy In Botswana.

Sikhulile Moyo, Hermann Bussmann, Phibeon Mangwendeza, Priti Dusara, Tendani Gaolathe, Madisa Mine, Rosemary Musonda, Erik van Widenfelt, Vladimir Novitsky, Joseph Makhema and 3 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of antivirals & antiretrovirals, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04930744 (A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People Co-infected With HIV), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04930744 phase2completednot on this mapstarted 2022, after this paper: background citation

A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People Co-infected With HIV

TypeinterventionalSponsorUniversity of Massachusetts, WorcesterRan2022 to 2025Enrolled112ConditionsTuberculosis, Pulmonary Tuberculosis, HIV CoinfectionArmsIsoniazid, Rifampicin, Ethambutol, Pyrazinamide, Metformin hydrochoride
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 2 countries.

Sikhulile MoyoBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Hermann Bussmann
Phibeon Mangwendeza
Priti Dusara
Tendani Gaolathe
Madisa Mine
Rosemary Musonda
Erik van Widenfelt
Vladimir Novitsky
Joseph Makhema
Richard G Marlink
Max Essex
C William Wester
Botswana Harvard AIDS Institute Partnership · BW

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Risk Factors for the Development of Lactic Acidosis and Pancreatitis Among HAART-K23AI073141 · NIAID · VANDERBILT UNIVERSITY · PI WESTER, C. WILLIAM · 2007 to 2011
$643k
NIAID NIH HHS K23 AI073141NIAID NIH HHS P30 AI060354
6 · The paper itself

Abstract

backgroundNucleoside reverse-transcriptase inhibitors (NRTIs) are a major component of combination antiretroviral therapy (cART) worldwide but they have been associated with mitochondrial toxicities, with one of the most significant being lactic acidosis. In southern Africa, being female and overweight (BMI > 25) as well as receiving d4T and/or ddI-based cART are risk factors for the development of this potentially life-threatening complication. It is challenging in many resource-limited settings to obtain reliable serum lactate measurements while screening for the presence of lactic acidosis. Point-of-care devices, however, are now available that provide simple, accurate measurements of serum lactate levels at relatively low cost. The objective of this study was to assess the agreement of the portable (Accutrend™ handheld) lactate analyzer to the conventional laboratory system for obtaining serum lactate.

methodsEighty two "at-risk" cART-treated adults were evaluated, having their lactate levels tested in parallel using both modalities.

resultsThe mean (range) lactate level for the portable device was 2.28 (0.9-5.0) compared to 1.96 (0.7-5.4) using the conventional method. There was a strong correlation (p<0.05) between the portable device and the conventional means with a Pearson correlation coefficient of 0.92 [95% CI: 0.88-0.95]. The mean bias was 0.33 [95% CI: -0.39-1.04], with the portable device having slightly higher values.

conclusionThe use of a portable lactate device provides an accurate and user-friendly means of screening at-risk patients for the presence of lactic acidosis in resource-limited settings with limited laboratory capacity.

Identifiers

PMID23087782
PMCPMC3475318
OpenAlexW2135611625

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.